| Literature DB >> 32425376 |
Archit Joshi1, Manikandan Dhanushkodi1, Prasanth Ganesan1, Venkatraman Radhakrishnan1, Krishnarathinam Kannan1, Nikita Mehra1, Jayachandran Perumal Kalaiyarasi1, S Krupashankar1, Shirley Sundersingh2, T S Ganesan1, T G Sagar1.
Abstract
HCL is an uncommon B cell lympho-proliferative disorder with high remission rates. There is paucity of data on the long-term outcome of HCL from India. We retrospectively collected data from individual case records of patients with HCL who were treated in Cancer Institute, Chennai from January 2001 until January 2018. Sixteen patients were diagnosed with HCL and were treated with cladribine (81%), interferon (13%) and one patient received only best supportive care (6%). All the treated patients achieved complete response. More than half of the patients developed febrile neutropenia but there were no treatment related mortality. The 5-year DFS was 77% and 5-year OS was 80%. Relapse of disease was seen in 27%. HCL is a curable malignancy with high remission rates and survival comparable to patient treated in west. © Indian Society of Hematology and Blood Transfusion 2019.Entities:
Keywords: Hairy cell leukemia; Outcome; Survival
Year: 2019 PMID： 32425376 PMCID： PMC7229049 DOI： 10.1007/s12288-019-01199-2
Source DB: PubMed Journal: Indian J Hematol Blood Transfus ISSN： 0971-4502 Impact factor: 0.900